Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accounts Payables: 2021-2024

Historic Accounts Payables for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Autolus Therapeutics' Accounts Payables rose 673.41% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 673.41%. This contributed to the annual value of $2.0 million for FY2024, which is 1811.65% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Accounts Payables of $2.0 million as of FY2024, which was up 1,811.65% from $103,000 recorded in FY2023.
  • Autolus Therapeutics' 5-year Accounts Payables high stood at $2.0 million for FY2024, and its period low was $103,000 during FY2023.
  • In the last 3 years, Autolus Therapeutics' Accounts Payables had a median value of $531,000 in 2022 and averaged $867,667.
  • Its Accounts Payables has fluctuated over the past 5 years, first slumped by 80.60% in 2023, then skyrocketed by 1,811.65% in 2024.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Accounts Payables stood at $431,000 in 2021, then grew by 23.20% to $531,000 in 2022, then plummeted by 80.60% to $103,000 in 2023, then surged by 1,811.65% to $2.0 million in 2024.